CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the appointment of Jolie M. Siegel as general counsel, a newly created position. Ms. Siegel will lead the legal, intellectual property, compliance and corporate governance functions for the company and will report to Hugh O’Dowd, president and chief executive officer of Neon.
“Jolie will be an invaluable resource as we advance the clinical trials of our personalized and precision therapeutics,” said Mr. O’Dowd. “We’re delighted to welcome her to the Neon team.”
“By directing the immune system more precisely to tumor cells, Neon’s neoantigen therapies have the potential to increase the efficacy of immunotherapy and improve patient outcomes,” Ms. Siegel said. “I am thrilled to join Neon at this important juncture in the company’s development.”
Before joining the company, Ms. Siegel served as senior vice president, deputy general counsel and assistant secretary at Intralinks, Inc., a leading financial technology provider for the global banking, deal making and capital markets communities. Previously, she was a partner at Choate Hall & Stewart LLP, where she worked on corporate transactional, securities and general business matters, with an emphasis on private equity, venture capital and high-growth companies. Earlier in her career, Ms. Siegel was an attorney at Testa, Hurwitz, & Thibeault, LLP.
Ms. Siegel received her Juris Doctor from the University of Pennsylvania Law School and her Bachelor of Arts in political science from the University of Pennsylvania, where she graduated cum laude.
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens.
For more information, please visit www.neontherapeutics.com.
This press release contains “forward-looking statements” of Neon Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our ability to obtain and maintain regulatory approval of our product candidates; regulatory developments in the United States and foreign countries; and the ability of our product candidates to contribute to or cause positive outcomes for patients. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to our ability to protect and maintain our intellectual property position; risks related to the ability of our licensors to protect and maintain their intellectual property position; uncertainties related to the initiation and conduct of studies and other development requirements for our product candidates; the risk that any one or more of our product candidates will not be successfully developed and commercialized; the risk that the results of preclinical studies and clinical trials will be predictive of future results in connection with future studies or trials; and the risk that Neon’s collaborations will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Neon’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Neon’s most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Neon’s other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Neon undertakes no duty to update this information unless required by law.
Stephanie Simon, Ten Bridge Communications
Will O’Connor, Stern Investor Relations